Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients

Abstract

Background:

Clinically, some patients whose HBsAg becomes negative owing to antiviral therapy or spontaneously still show a low level of HBV DNA persistence in serum. T-lymphocyte subsets, cytokine levels and HBV S gene sequences were analyzed in this study.

Methods:

A total of 52 HBsAg-negative and HBV DNA-positive patients(HBsAg-/HBV DNA+ patients), 52 persistently HBsAg-positive patients(HBsAg+/HBV DNA+ patients) and 16 healthy people were evaluated. T-lymphocyte subsets of these patients were detected by flow cytometry, serum cytokines and chemokines were detected by the Luminex technique, and the HBV S region was evaluated by Sanger sequencing. T%, T-lymphocyte, CD8+ and CD4+T lymphocyte were lower in the HBsAg-negative group than in the HC group. Compared with the HBsAg-positive group, the HBsAg-negative group had lower levels in T lymphocyte %, CD8+T lymphocyte %, CD8+T lymphocyte and CD4/CD8. These difference were statistically significant (P<0.05). Serum IFN-γ, IFN-α and FLT-3L levels were significantly higher in the HBsAg-negative group than in the HBsAg-positive group (P<0.05). However, levels of many cytokines related to inflammation (i.e., IL-6, IL-8, IL10, IL-12, IL-17A) were lower in the HBsAg-negative group. Fifty-two HBsAg-negative samples were sequenced, revealing high-frequency amino acid substitution sites in the HBV S protein, including immune escape mutations (i.e., Y100C, S114T, C124Y, P127L, G130R, T131N, M133T, C137S, G145A) and TMD region substitutions (i.e., E2K/R/D, G7D/R, G10D, A17R, F20L/S, L21V, L22V).

Conclusions:

According to the results of T-lymphocyte subsets and serum cytokines, it can be deduced that the cellular immune function of HBsAg-negative patients is superior to that of HBsAg-positive patients, with attenuation of liver inflammation. HBsAg-negative patients may show a variety of mutations and amino acid replacement sites at high frequency in the HBV S region, and these mutations may lead to undetectable HBsAg, HBsAg antigenic changes or secretion inhibition.

Materials and methods

Population studied

This is a cross-sectional study. Between May 2019 and May 2022, 279 patients who were HBsAg negative(<0.05 IU/mL, S/CO<1) and HBV DNA positive(≥10 IU/mL) were screened by hospital data systems. Only 52 of the 279 patients had persistent HBsAg-/HBV DNA+ serological status(>3 months). They had all been diagnosed with chronic hepatitis B in the past. 52 HBsAg+/HBV DNA+ patients who were diagnosed with chronic hepatitis B were matched by sex, age, and disease type. At the same time, clinical residual serum samples from 16 healthy people were collected as the control group. The criteria for healthy subjects were: healthy, no liver disease, no other diseases, and normal laboratory tests. The HBsAg-positive patient samples came from the patient's first blood draw after admission, before antiviral treatment. The diagnostic criteria are based on WHO guidelines for the prevention and treatment of chronic hepatitis B (2019 version) (12). The exclusion criteria were as follows: HBV infection window period; HCV infection not combined with other viral infections; alcoholic liver disease; streptocarpus; drug-induced liver injury; autoimmune diseases, hematological tumors and other serious genetic and metabolic diseases; use of immunosuppressants and hormones within the past three months; and post chemotherapy. The study was approved by the Medical Ethics Committee of Capital Medical University, Beijing Youan Hospital. Because the study used clinical residual serum samples, it was exempt from informed consent.

Laboratory assays

Roche automatic immaterialize was routinely used to detect serum HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc at the hospital clinical examination center. HBsAg titer<0.05 IU/mL and anti-HBs<10 IU/L, HBeAg S/CO<1, or anti-HBe and anti-HBc S/CO>1 was considered negative. Quantitative detection of serum HBV DNA was carried out by Abbott Real-Time fluorescence quantitative PCR. The lower limit of quantification was 10 IU/mL (34.1 HBV DNA copies/mL) in the 0.5 mL sample preparation protocol. The results of the assay were expressed as undetected, detectable but below the lower limit of quantification (i.e., HBV DNA detected but not quantifiable), and calculated results in IU/mL within the linear range of the assay. The Siemens Aptio automatic biochemical assembly pipeline was used to detect liver function indexes, such as serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL).

Detection of peripheral blood T-lymphocyte subsets

Whole-blood samples were analyzed using a BECKMAN flow cytometer (Coulter, USA). Lymphocytes were analyzed using a gate set on a forward scatter vs. side scatter, and three-color flow cytometry was applied to combine CD3, CD4 and CD8. The peripheral blood T-lymphocyte subsets detected in each sample were analyzed using CellQuest software (Coulter, USA).

Cytokine and chemokine profiles

We use MILLIPLEX MAP Human Cytokine/Chemokine/Growth Factor Panel A 48 Plex Premixed Magnetic Bead Panel Kit (Merck, USA) following the manufacturer’s recommendations and a Luminex MAGPIX Instrument System, as used for simultaneous quantification of any or all of the following analytes in human tissue/cell lysate and culture supernatant samples and serum or plasma samples: Soluble Cluster of Differentiation 40 Ligand (sCD40L), epidermal growth factor (EGF), Eotaxin, fibroblast growth factor 2 (FGF-2), Fms-related tyrosine kinase 3 ligand (FLT-3L), Fractalkine, granulocyte-stimulating factor(G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), growth-regulated oncogene-α (GRO-α), interferon-α2 (IFN-α2), interferon-γ (IFN-γ), IL-1α, IL-1β, interleukin 1 receptor antagonist (IL-1RA), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1/CCL2), MCP-3, macrophage-stimulating factor(M-CSF), macrophage-derived chemokine (MDC), monokine induced by IFN-γ (MIG/CXCL9), macrophage inflammatory protein 1α (MIP-1α/CCL3), MIP-1β/CCL4, platelet-derived growth factor AA (PDGF-AA), PDGF-AB/BB, regulated upon activation normal T-Cell expressed and presumably secreted (RANTES/CCL5), TGF-α, tumor necrosis factor α (TNF-α), TNF-β/lymphotoxin alpha (LTA), and vascular endothelial growth factor A (VEGF-A). Serum cytokine profiles were quantitatively measured in 52 HBsAg-negative and HBV DNA-positive patients, 52 HBsAg-positive patients and 16 healthy subjects. MILLIPLEX® products are based on Luminex xMAP technology. Cytokines with more than 50% missing data were not analyzed. Cytokine concentrations have an intra-assay coefficient of variation within 15%. As 4 of the 48 cytokines were not detectable in more than 50% of the samples (GM-CSF, IL-3, IL-7, IL-22), these four cytokines were not analyzed. A variety of cytokine levels are shown in the Supplementary Materials.

Sequencing analysis of the HBV S region

HBV DNA was extracted from 1.0 ml of serum using the silica gel membrane centrifugal column method. First-round and second-round PCR were performed to amplify the HBV S region using PrimeSTAR MAX DNA polymerase. The primers used for both rounds of PCR were PF (5’-TTCCTGC TGGTGGCTCCAGTTC-3’, nt54-75) and PR (5’-TTCCGCAGTATGGATCGGCAG-3’, nt1258-1278), amplifying a 1224-bp fragment. PCR amplicons were assessed by 1% agarose gel electrophoresis (200 V for 20 min), and positive amplicons were purified. Both strands of purified amplification products were sequenced directly using ABI 3730xl DNA Analyzer. Homology evaluations were performed with the GenBank database using BLAST analysis at https://www.ncbi.nlm.nih.gov. Nucleic and amino acid sequences were analyzed using MEGA 7.0 software. HBV was genotyped based on the full sequence of the S gene using an online prediction tool (https://hbv.geno2pheno.org/index.php). Amino acid substitutions were determined by comparing specimen sequences to the genotype consensus sequence from the alignment of genotype sequences downloaded from https://www.ncbi.nlm.nih.gov. The immune escape mutation of the HBV S protein was determined by the Geno-2-pheno-hbv tool (https://hbv.geno2pheno.org/index.php).

Statistical analysis

Statistical analysis was performed using SPSS 26.0. Single-factor ANOVA was employed for comparison of continuous variables following a normal distribution and the SNK-q test for comparisons between groups. A t test was used to compare two groups of continuous variables. The Kruskal-Wallis H test was used to compare continuous variables with a nonnormal distribution between groups, and the Mann-Whitney U test was used to compare the two groups. Two groups of classifying variables were compared using the X² test. Continuous variables are expressed as (±s) or the median (P25-P75), and a difference was considered to be statistically significant at P< 0.05. GraphPad Prism 8 was utilized for the statistical analysis.

Results

Basic clinical data and laboratory test results

The HBsAg-negative patients were mainly male, at 76.92% (40/52), and the mean age was 53 years old. Most of the HBsAg-negative patients had received antiviral therapy with nucleotide analogs and/or interferon according to their clinical history. The positive rates of anti-HBs and anti-HBe in HBsAg-negative patients were significantly higher than those among HBsAg-positive patients[51.92%(27/52) vs. 0.00%(0/52), 80.77% (42/52) vs. 57.69%(30/52)] (P<0.05). A total of 80.77% of HBsAg-negative patients had HBV DNA below 200 IU/mL, and the median value of HBV DNA load was significantly lower than that of HBsAg-positive patients (log, 1.76 vs. 5.77 IU/mL) (P<0.05). Compared with HBsAg-positive patients, median levels of ALT, AST and TBA in HBsAg-negative patients were lower (36 vs. 103 U/L, 38 vs. 92 U/L and 12.40 vs. 120.00 μmol/L), and the differences were significant (P<0.05) (Table 1).

Characteristics of peripheral blood T-lymphocyte subsets

The number of T lymphocytes and CD8+T lymphocytes decreased successively in the healthy control group, HBsAg-negative group and HBsAg-positive group. Each group of data was compared with the mean and median(Table 2). Levels of T lymphocytes and CD8+ T lymphocytes in HBsAg-negative group were higher than HBsAg-positive group, and the difference was statistically significant (P<0.05). The number of T-lymphocyte subsets in the HBsAg negative group and HBsAg positive group was lower than that in the healthy control group. Ratios of T lymphocytes/lymphocytes(T lymphocyte%), T lymphocytes, CD8+T lymphocytes/ lymphocytes(CD8+T lymphocyte%) and CD8+T lymphocytes in the HBsAg-negative group were significantly lower than those in the HBsAg-positive group(P<0.05). However, the CD4/CD8 ratio was the highest in HBsAg-positive group, and the difference was statistically significant compared with the other two groups(P<0.05). There was no difference in the CD4/CD8 ratio between HBsAg-negative group and healthy control group (Figure 1).

Figure 1

Levels of serum cytokines and chemokines

By comparing median levels of cytokines and chemokines between the HBsAg-negative group and HBsAg-positive groups, significant differences in IFN-γ, IFN-α, FLT-3L, IP-10, TNF-α, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12, IL-15 IL-17A and IL-18 were found (P<0.05). Additionally, higher median values of IFN-γ, IFN-α and FLT-3L were detected in the HBsAg-negative group and higher median levels of IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12, IL-15, IL-17A and IL-18 were detected in the HBsAg-positive group (Figure 2, Table 3). Among the 48 cytokines and chemokines detected, 14 each showed significant differences between the two groups, with the other cytokines having no significant difference. Furthermore, median levels of IFN-γ and FLT-3 L in the HBsAg-positive group were lower than those in the HBsAg-negative group and healthy controls, with significant differences (P<0.05); median values of IFN-α were highest in the HBsAg-negative group, with significant differences between groups (P<0.05). Moreover, median levels of IFN-α, IP-10, TNF-α, IL-1β, IL-2, IL-8, IL-10, IL-12, IL-15, IL-17A and IL-18 were higher in the HBsAg-negative and HBsAg-positive groups than in the healthy controls, a statistically significant difference (P<0.05). The median (P25-P75) and differences in cytokines in the three groups are shown in Figure 2 and Table 3.

Figure 2

HBV S region mutation and amino acid substitution in HBsAg-negative and HBV DNA-positive patients

Only 43 of 52 HBsAg-negative samples were successfully sequenced; thus, 43 HBV S gene sequences were analyzed. Genotypes of HBV were determined according to the S gene sequence. Of the 30 HBV S region fragments identified in HBsAg-negative strains, 30 were classified as genotype B (30/43, 69.77%) and 13 strains as genotype C (13/43, 31.23%). DNA sequencing revealed an amino acid substitution in the HBV S protein in 39 of the 43 (90.70%) HBsAg-negative and HBV DNA-positive patients. E kinds of immune escape mutation sites were detected in the genotype B HBV S protein, namely, G119D, T126I, T127P, A128V, G130R, S132F, M133K and C137S, in six HBsAg-negative and HBV DNA-positive patients (6/43, 13.95%). Additionally, 8 kinds of immune escape mutation sites were detected in the genotype C HBV S protein in five HBsAg-negative and HBV DNA-positive patients: Y100C, S114T, C124Y, P127L, G130R, T131N, M133T and G145A (5/43, 11.63%). Amino acid substitution in the transmembrane domain (TMD) region was observed in 31 HBsAg-negative patients (31/43, 72.09%), but only 8 HBsAg-negative samples showed an amino acid substitution in the "α" determinant (amino acids 124-147) of the S protein (Table 4). One female patient’s HBV DNA load was as high as 7.81×10⁵ IU/mL, but HBsAg was negative after antiviral treatment with entecavir. In her sample, we detected many HBV S region mutations resulting in multiple amino acid replacement sites, including immune escape mutations (S114T, C124Y, P127L, G130R, T131N and M133T) and TMD region mutations (L8H, V14A, F19S, V168A, S174N, L175S, Q181R and P203R). There were also three patients with high HBV DNA loads at more than 1×10⁴ IU/mL, and they also showed many HBV S region mutations (Table 4).

Amino acid substitution frequency in HBV S protein

A total of 43 samples from HBsAg-negative patients and 49 samples from HBsAg-positive patients were successfully sequenced. Among 43 HBV S-region sequences in HBsAg-negative patients, 30 (30/43, 69.77%) were genotype B and 13 (13/43, 31.23%) genotype C; 34 of 49 (34/49, 69.39%) HBV S-region sequences in HBsAg-positive patients were genotype B and 15 (15/49, 31.23%) genotype C. The mutation rate of the HBV S protein in HBsAg-negative patients was 90.70% (39/43) and that in HBsAg-positive patients was 28.57% (14/49), significantly higher in HBsAg-negative patients. F20L/S (9/30, 30.00%) displayed the highest occurrence frequency in HBsAg-negative patients with genotype B, followed by L22V (5/30, 16.67%) and G10D (5/30, 16.67%). The frequency of multiple immune escape mutations in HBsAg-negative patients with the B and C genotypes was higher than that in HBsAg-positive patients. A variety of amino acid substitution sites also occurred at high frequency in the TMD region of the S protein in HBsAg-negative patients. The details of amino acid substitution frequencies for HBsAg-negative and HBsAg-positive patients are provided in Table 5.

Discussion

In this study, HBsAg-negative patients were treated with antiviral therapy or spontaneously experienced a gradual decrease in HBsAg titer until it disappeared; the HBV DNA load also decreased but remained at a low level in serum. This paper describes T-lymphocyte subsets, various cytokine levels and HBV S gene mutations in HBsAg-negative and HBV DNA-positive patients. The subjects of this study were clinically HBsAg-negative and HBV DNA-positive patients, and their serological characteristics and viral load were the same as those of OBI patients among blood donors in previous studies (18–20). Hence, regardless of whether HBsAg-negative cases are caused by antiviral therapy or naturally occurring OBI, clinical indicator characteristics are the same.

HBeAg is a marker of active HBV DNA replication in hepatocytes. However, most HBsAg-negative patients are negative for HBeAg, suggesting low viral replication in these patients. The positive rates of anti-HBs and anti-HBe in HBsAg-negative and HBV DNA-positive patients in our study were 51.92% and 80.77%, respectively, significantly higher than those in HBsAg-positive patients. Thus, most HBsAg-negative patients have undergone serological conversion, with low levels of viral replication and protein expression. To explore the host immune function and inflammatory state in HBsAg-negative patients, levels of T lymphocyte subsets and serum cytokines were analyzed in this study; the HBV S gene was also sequenced and analyzed. Despite suppression of HBV DNA replication and protein expression, the virus may not be completely eliminated. In fact, a small amount of HBV cccDNA remains in liver tissue, with the potential to progress to cirrhosis and hepatocellular carcinoma. As it is considered a risk factor for hepatocellular carcinoma, it cannot be ignored (21–23).

Some studies have suggested that HBsAg-negative and HBV DNA-positive cases are related to viral genome mutations, that is, HBsAg antigenicity changes in HBsAg-negative and HBV DNA-positive patients with mutations in the HBV PreS/S region. Mutations located in the immunodominant "α" determinant region (aa124-147 or 149) can impair the efficiency of HBsAg detection reagents by reducing the binding affinity of the HBsAg capture antibody (24). A single mutation in the "α" determinant in the main hydrophilic region (MHR) of the HBV S region can also inhibit HBsAg secretion (25). Additionally, amino acid substitution in the reverse transcriptase (RT) domain may lead to low levels of HBV DNA replication and HBsAg synthesis, resulting in HBsAg-negative and HBV DNA-positive cases (26). The substitutions M133T and T131N generate an extra N-linked glycosylation site that reportedly does not affect HBsAg secretion but may mask antigenic sites affecting detection (27). Moreover, the mutants Y100C and P127L may affect HBsAg expression and secretion as well as anti-HBs binding (28).

Among the 43 successfully sequenced HBsAg-negative samples, 39 HBV S region fragments showed mutations; among HBsAg-positive samples, 49 samples were sequenced successfully, and 14 HBV S region fragments showed mutations. The mutation rate of the HBV S gene in HBsAg-negative patients (39/43, 90.70%) was significantly higher than that in HBsAg-positive patients (14/49, 28.57%) in our study. Six HBsAg-negative samples showed immune escape mutation sites in the genotype B HBV S region, G119D, T126I, T127P, A128V, G130R, S132F, M133K and C137S (29), with immune escape mutation sites in the genotype C HBV S region in five HBsAg-negative samples, Y100C, S114T, C124Y, P127L, G130R, T131N, M133T and G145A (29). No immune escape mutation was detected in HBsAg-positive patients. These HBsAg immune escape mutants may have arisen as a result of specific selection, such as through the host immune system due to vaccination or antiviral selective pressure attenuating production of HBsAg and resulting in low plasma HBV DNA levels (30). Furthermore, these mutations may be responsible for virus detection failure in routine screening (25). Indeed, this is common in the clinical setting in which patients may have HBsAg-negative results but classical symptoms and, if tested for HBV DNA, will show high HBV DNA levels. In general, detection of some of these emerging mutants has become a major challenge for commercially available immunoassays. Thirty-one HBsAg-negative samples in the TMD region exhibited multiple amino acid substitution sites, many of which were newly discovered, such as E2K/R/D, G10D, A17R, F20L/S, L21V, L22V, F200Y, and S204N. E2 site mutations in the S protein are confirmed to impair secretion of HBsAg, which significantly affected detection of HBsAg (31). For genotype B, the highest mutation frequency of the S protein in HBsAg-negative patients was sF20L/S; regarding genotype C, sF19V/S had the highest frequency. Both mutations occur in the TMD region of the S protein. sF20L/S and sF19V/S are high-frequency mutations associated with HBsAg negativity, which may be a result of the pressure of antiviral therapy and have certain effects on HBsAg production or secretion. The truncation mutant sW182* was present in one HBsAg-negative patient in the study of Pollicino et al (32). This mutation induces retention of the truncated S protein in the perinuclear endoplasmic reticulum (ER) and is associated with lower HBV transcript levels due to decreased stability (33). Large-scale studies and in vitro experiments are needed to determine the significance of newly detected mutations.

Studies have shown that the immune system of HBsAg-negative and HBV DNA-positive patients strongly inhibits viral replication and gene expression (34–37). The ability of CD8 T lymphocytes to proliferate and secrete cytokines (e.g., IFN-γ, IL-2) is weakened in chronic HBV infection (38), and T-lymphocyte subsets can be used to assess the immune function of the host. As cytokines can alter the process of infection and affect the tendency and progression of chronic hepatitis B, they are worthy of study.

In this study, the number of CD4+ T lymphocytes, CD8+ T lymphocytes, CD4+ T lymphocytes/lymphocytes (CD4+ T%) and CD8+ T lymphocytes/lymphocytes (CD8+ T%) was lowest in the HBsAg-positive group, which may be related to the low immune function caused by chronic HBV infection. The numbers of CD4+ T cells and CD8+ T cells in the HBsAg-negative group were higher than those in the HBsAg-positive group. Levels of a variety of cytokines and chemokines (IFN-γ, IFN-α, FLT-3 L) related to immune regulation and virus clearance were also higher in the HBsAg-negative group. Therefore, the immune function of HBsAg-negative patients is enhanced compared with HBsAg-positive patients, which may be related to virus suppression in the former after antiviral treatment. The immune function of HBV-infected patients treated with antiviral interferon may also be enhanced, which can increase the clearance rate of HBsAg. Because this study was a cross-sectional study and we could only determine T lymphocyte subsets and serum cytokine levels after HBsAg clearance, it is unclear whether enhanced host immune function occurred before or after HBsAg clearance. Regardless, it can be confirmed that HBsAg-negative patients have strong host immune function. Although the number of CD4 and CD8 T cells in the HBsAg-negative patients was higher than that in the HBsAg-positive patients, it was lower than that in the healthy controls. Therefore, the immune function of HBsAg-negative patients did not completely recover to the normal level, which corresponds to the low level of serum HBV DNA in HBsAg-negative patients. A high level of HBsAg is associated with impairment of anti-HBV-specific T and B-cell immune function. Reducing the HBsAg level should promote recovery of specific immune function and in turn promote clearance of HBsAg (39, 40). In this study, we only analyzed the increase in overall T-lymphocyte subsets in HBsAg-negative patients and did not detect the immune function of HBV-specific T lymphocytes. Further research is needed.

Cytokines represent a large family of molecules, including the following: Th1-associated cytokines [e.g., IL-2 and IFN-γ], which have a functional contribution to cellular immune responses; Th2-associated cytokines (e.g., IL-4, IL-6, and IL-10), which have roles in humoral immune responses; regulatory T-cell (Treg)-associated cytokines [e.g., tumor growth factor-beta (TGF-β) and IL-10], which have been associated with immunomodulation and immunosuppression; and Th17-associated cytokines (e.g., IL-17, IL-22, and IL-23), which play critical roles in mediating inflammation (41). There are few studies on the production profile of cytokines and chemokines in HBsAg-negative and HBV DNA-positive patients, and the mechanism of liver injury is still unclear, but some studies have shown that persistence and transcription of HBV cccDNA in hepatocytes can stimulate production of cytokines, such as TNF-α and IFN-γ, resulting in hepatocyte injury (17). We conclude that levels of TNF-α and IFN-γ in HBsAg-negative patients are significantly higher than those in healthy subjects, which may be related to a small amount of HBV in the body. The persistence and transcription of HBV cccDNA in hepatocytes can lead to the production of cytokines, such as TNF-α and INF-γ (38). Cytokines and chemokines are essential effector molecules in the HBV-related inflammatory response. CD4+ T cells, CD8+ T cells, NK cells, DC cells and their related cytokines participate in the immune injury process of chronic HBV infection (42, 43).

In addition, IFN-γ, IFN-α and FLT-3 L levels in HBsAg-negative patients were significantly higher than those in HBsAg-positive patients in our study. High HBV DNA load and high HBeAg and HBsAg levels may inhibit immune cell function, leading to a reduction in FLT-3L, IFN-γ, and other cytokines with virus clearance effects and to an increase in the level of the most important cytokine for immunosuppression: IL-10 (43–45). HBsAg induces depletion phenotypes and dysfunction of T and B cells, leading to innate and adaptive immune deficiencies, and lowering serum HBsAg contributes to recovery of the host immune response (46). The increase in IFN-γ and FLT-3 L in the HBsAg-negative patients in the present study may be due to the decrease in HBV DNA and clearance of HBsAg after the use of nucleotide analog antiviral drugs. HBV DNA reduction and HBsAg clearance in HBsAg-negative patients after antiviral therapy may promote recovery of cellular immune function, thus leading to increased serum IFN-γ and FLT-3L levels. In general, levels of various proinflammatory cytokines (IL-2, IL-4, IL-8, IL-10, IL-12, IL-15, IL17A, IL-18) in HBsAg-positive patients were higher than those in HBsAg-negative patients and healthy people. Compared with HBsAg-positive patients, the inflammatory reaction of HBsAg-negative patients was reduced and the immune response function enhanced, but they were still in a state of HBV infection. Overall, a mild inflammatory response compared to healthy people was observed.

Conclusion

High HBsAg serum levels lead to failure of the host immune system, preventing an effective antiviral response. Levels of HBsAg and virus decrease after antiviral treatment, and the inhibitory effect on host cellular immune function is weakened. Cellular immune function is gradually enhanced, which further increases the virus clearance effect. However, HBV S gene mutation may occur in HBsAg-negative patients during antiviral therapy, which leads to amino acid substitutions in the S protein. If the mutation occurs in the main hydrophilic region, the antigenicity of the surface antigen would be changed, rendering commercial detection reagents unable to detect it. If the mutation occurs in the TMD region and changes the S protein conformation, it may affect production and secretion of HBsAg and result in a concentration of serum HBsAg lower than the limit of detection. The decrease in HBsAg secretion is beneficial to host cellular immune function, and antiviral immune responses are continuously stimulated by persistent/intermittent low levels of HBV antigens. This study found a variety of new high-frequency mutation sites in clinically HBsAg-negative and HBV DNA-positive patients.

References

• 1

  StasiCSilvestriCVollerF. Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res (2020) 9(1):1–7. doi: 10.7774/cevr.2020.9.1.1

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol (2017) 67(2):370–98. doi: 10.1016/j.jhep.2017.03.021

  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  LocarniniSRaimondoG. How infectious is the hepatitis B virus? Readings from the occult. Gut (2019) 68(2):182–3. doi: 10.1136/gutjnl-2018-316900

  • CrossRef
  • Google Scholar

• 4

  HoofnagleJHSeeffLBBalesZBZimmermanHJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 298(25):1379–83. doi: 10.1056/NEJM197806222982502

  • CrossRef
  • Google Scholar

• 5

  ChoHJCheongJY. Role of immune cells in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Mol Sci (2021) 22(15):8011. doi: 10.3390/ijms22158011

  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  BréchotCHadchouelMScottoJFonckMPotetFVyasGNet al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and negative liver diseases. Proc Natl Acad (1981) 78:3906–10. doi: 10.1073/pnas.78.6.3906

  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  JiangXChangLYanYWangL. Paradoxical HBsAg and anti-HBs coexistence among chronic HBV infections:causes and consequences. Int J Biol Sci (2021) 17(4):1125–37. doi: 10.7150/ijbs.55724

  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  WuYZhuZWuJBiWXuWXiaXet al. Evolutionary analysis of pre-S/S mutations in HBeAg-negative chronic hepatitis B with HBsAg< 100 IU/ml. Front Public Health (2021) 9:633792. doi: 10.3389/fpubh.2021.633792

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  Yong-LinYQiangFMing-ShunZJieCGui-MingMZu-HuHet al. Hepatitis B surface antigen variants in voluntary blood donors in Nanjing, China. Virol J (2012) 9:82. doi: 10.1186/1743-422X-9-82

  • CrossRef
  • Google Scholar

• 10

  ZhuHLLiXLiJZhangZH. Genetic variation of occult hepatitis B virus infection. World J Gastroenterol (2016) 22(13):3531–46. doi: 10.3748/wjg.v22.i13.3531

  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  XueYWangMJYangZTYuDMHanYHuangDet al. Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant. Emerg Microbes Infect (2017) 6(3):e15. doi: 10.1038/emi.2017.2

  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  WuJHanMLiJYangXYangD. Immunopathogenesis of HBV infection. Adv Exp Med Biol (2020) 1179:71–107. doi: 10.1007/978-981-13-9151-4_4

  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  KhanamAChuaJVKottililS. Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression. Int J Mol Sci (2021) 22(11):5497. doi: 10.3390/ijms22115497

  • CrossRef
  • Google Scholar

• 14

  NguyenLNNguyenLZhaoJSchankMDangXCaoDet al. Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection. Hepatology (2021) 74(5):2380–94. doi: 10.1002/hep.32008

  • CrossRef
  • Google Scholar

• 15

  BertolettiAFerrariC. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut (2012) 61(12):1754–64. doi: 10.1136/gutjnl-2011-301073

  • CrossRef
  • Google Scholar

• 16

  Martinot-PeignouxMLapalusMAsselahTMarcellinP. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int (2013) 33(Suppl 1):125–32. doi: 10.1111/liv.12075

  • CrossRef
  • Google Scholar

• 17

  RibeiroCRde AlmeidaNAMartinelliKGPiresMAMelloCEBarrosJJet al. Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients. Virol J (2021) 18(1):15. doi: 10.1186/s12985-021-01487-2

  • CrossRef
  • Google Scholar

• 18

  LiuCJChenDSChenPJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol (2006) 36(Suppl 1):S33–44. doi: 10.1016/S1386-6532(06)80007-7

  • CrossRef
  • Google Scholar

• 19

  YeXLiuLChenLNieXHuangLYeDet al. High-frequency notable HBV mutations identified in blood donors with occult hepatitis B infection from heyuan city of southern China. Front Immunol (2022) 13:754383. doi: 10.3389/fimmu.2022.754383

  • CrossRef
  • Google Scholar

• 20

  FopaDCandottiDTagnyCTDouxCMbanyaDMurphyELet al. Occult hepatitis B infection among blood donors from Yaoundé, Cameroon. Blood Transfus (2019) 17(6):403–8. doi: 10.2450/2019.0182-19

  • CrossRef
  • Google Scholar

• 21

  WangJLiuYLiaoHLiuLChenRSiLet al. The sK122R mutation of hepatitis B virus (HBV) is associated with occult HBV infection: Analysis of a large cohort of Chinese patients. J Clin Virol (2020) 130:104564. doi: 10.1016/j.jcv.2020.104564

  • CrossRef
  • Google Scholar

• 22

  SimonettiJBulkowLMcMahonBJHOmanCSnowballMNegusSet al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology (2010) 51(5):1531–7. doi: 10.1002/hep.23464

  • CrossRef
  • Google Scholar

• 23

  ChenLZhaoHYangXGaoJYChengJ. HBsAg-negative hepatitis B virus infection and hepatocellular carcinoma. Discovery Med (2014) 18(99):189–93.

  • Google Scholar

• 24

  CaoGW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 15(46):5761–9. doi: 10.3748/wjg.15.5761

  • CrossRef
  • Google Scholar

• 25

  SalpiniRColagrossiLBellocchiMCSurdoMBeckerCAlteriCet al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology (2015) 61(3):823–33. doi: 10.1002/hep.27604

  • CrossRef
  • Google Scholar

• 26

  LiSZhaoKLiuSWuCYaoYCaoLet al. HBsAg sT123N mutation induces stronger antibody responses to HBsAg and HBcAg and accelerates in vivo HBsAg clearance. Virus Res (2015) 210:119–25. doi: 10.1016/j.virusres.2015.08.004

  • CrossRef
  • Google Scholar

• 27

  BiXTongS. Impact of immune escape mutations and N-linked glycosylation on the secretion of hepatitis B virus virions andsubviral particles: Role of the small envelope protein. Virology (2018) 518:358–68. doi: 10.1016/j.virol.2018.03.011

  • CrossRef
  • Google Scholar

• 28

  TaffonSGenoveseDBlasiMPierottiPDegli EspostiACatoneSet al. HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study. Infection (2014) 42(4):675–87. doi: 10.1007/s15010-014-0616-2

  • CrossRef
  • Google Scholar

• 29

  KimMHKangSYLeeWI. Occult HBV among anti-HBc alone: mutation analysis of an HBV surface gene and pre-S gene. Yonsei Med J (2017) 58(3):557–63. doi: 10.3349/ymj.2017.58.3.557

  • CrossRef
  • Google Scholar

• 30

  LiuYWangCMChengJLiangZLZhongYWRenXQet al. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin Med J (Engl) (2009) 122:1585–6.

  • Google Scholar

• 31

  WangHLiaoFXieJGaoWWangMHuangJet al. E2 site mutations in S protein strongly affect hepatitis B surface antigen detection in the occult hepatitis B virus. Front Microbiol (2021) 12:664833. doi: 10.3389/fmicb.2021.664833

  • CrossRef
  • Google Scholar

• 32

  PollicinoTAmaddeoGRestucciaARaffaGAlibrandiACutroneoGet al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology (2012) 56:434–43. doi: 10.1002/hep.25592

  • CrossRef
  • Google Scholar

• 33

  XiangKHMichailidisEDingHPengYQSuMZLiYet al. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. J Hepatol (2017) 66(2):288–96. doi: 10.1016/j.jhep.2016.09.005

  • CrossRef
  • Google Scholar

• 34

  PollicinoTRaffaGCostantinoLLisaACampelloCSquadritoGet al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 45(2):277–85. doi: 10.1002/hep.21529

  • CrossRef
  • Google Scholar

• 35

  PollicinoTBelloniLRaffaGPediconiNSquadritoGRaimondoGet al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 130(3):823–37. doi: 10.1053/j.gastro.2006.01.001

  • CrossRef
  • Google Scholar

• 36

  ToscaniniFDe LeoPCalcagnoGMalfattiFGrassoAAnselmoM. Hepatitis B reactivation in a HBsAg-negative, HBcAb-positive patient receiving fludarabine for the treatment of chronic lymphocytic leukaemia. Case Rep Hepatol (2011) 2011:258791. doi: 10.1155/2011/258791

  • CrossRef
  • Google Scholar

• 37

  HoofnagleJH. Reactivation of hepatitis B. Hepatology (2009) 49(5 Suppl):S156–65. doi: 10.1002/hep.22945

  • CrossRef
  • Google Scholar

• 38

  XiongSZhuDLiangBLiMPanWHeJet al. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine (2021) 69:103464. doi: 10.1016/j.ebiom.2021.103464

  • CrossRef
  • Google Scholar

• 39

  KondoYNinomiyaMKakazuEKimuraOShimosegawaT. Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection. ISRN Gastroenterol (2013) 2013:935295. doi: 10.1155/2013/935295

  • CrossRef
  • Google Scholar

• 40

  TsaiKNKuoCFOuJJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol (2018) 26(1):33–42. doi: 10.1016/j.tim.2017.07.006

  • CrossRef
  • Google Scholar

• 41

  HuangZvan VelkinburghJCNiBWuY. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int (2012) 32(6):894–901. doi: 10.1111/j.1478-3231.2012.02764.x

  • CrossRef
  • Google Scholar

• 42

  OhISParkSH. Immune-mediated liver injury in hepatitis B virus infection. Immune Netw (2015) 15(4):191–8. doi: 10.4110/in.2015.15.4.191

  • CrossRef
  • Google Scholar

• 43

  LiMZhangLXieSSunFZengZDengWet al. Dynamic changes of cytokine profiles and virological markers associated with HBsAg loss during peginterferon alpha-2a treatment in HBeAg-positive chronic hepatitis B patients. Front Immunol (2022) 13:892031. doi: 10.3389/fimmu.2022.892031

  • CrossRef
  • Google Scholar

• 44

  LiMHZhangDZhangLQuXJLuYShenGet al. Ratios of T-helper 2 cells to T-helper 1 cells and cytokine levels in. Chin Med J (2017) 130(15):1810–5. doi: 10.4103/0366-6999.211541

  • CrossRef
  • Google Scholar

• 45

  LiYFanWLinkFWangSDooleyS. Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease. JHEP Rep (2021) 4(2):100397. doi: 10.1016/j.jhepr.2021.100397

  • CrossRef
  • Google Scholar

• 46

  WuSYiWGaoYDengWBiXLinYet al. Immune mechanisms underlying hepatitis B surface antigen negative in chronic hepatitis B patients with viral coinfection. Front Immunol (2022) 13:893512. doi: 10.3389/fimmu.2022.893512

  • CrossRef
  • Google Scholar